Revolution Medicines (RVMD) Cash from Investing Activities (2019 - 2026)

Revolution Medicines' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $172.6 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 1182.29% year-over-year to $172.6 million in Q1 2026; TTM through Mar 2026 was $306.6 million, a 195.11% increase from a year earlier, with the FY2025 full-year figure at $118.1 million, up 121.29% from the prior year.
• Cash from Investing Activities climbed to $172.6 million in Q1 2026 per RVMD's latest filing, from $74.9 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $172.6 million in Q1 2026 and bottomed at -$392.9 million in Q4 2024.
• The 5-year median for Cash from Investing Activities is $4.0 million (2023), against an average of -$37.1 million.
• Across the five-year window, Cash from Investing Activities surged 1806.67% in 2022 and plunged 6305.36% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at -$7.1 million in 2022, then tumbled by 5254.76% to -$380.4 million in 2023, then dropped by 3.29% to -$392.9 million in 2024, then surged by 119.06% to $74.9 million in 2025, then jumped by 130.52% to $172.6 million in 2026.
• Per Business Quant, the three latest RVMD Cash from Investing Activities figures stand at $172.6 million (Q1 2026), $74.9 million (Q4 2025), and $24.8 million (Q3 2025).